1-phenyl-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline | 109697-95-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-phenyl-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline
• 英文别名: 1-Phenyl-2,3-dihydro-1H-pyrrolo[3,2-c]chinolin；1-Phenyl-2,3-dihydropyrrolo[3,2-c]quinoline
• CAS: 109697-95-2
• 化学式: C₁₇H₁₄N₂
• 分子量: 246.312
• InChiKey: CFYKZGWQVKIGBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-chloro-1-phenyl-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline 在 palladium on activated charcoal 、 乙醇 作用下， 生成 1-phenyl-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline
  参考文献：
  名称：

  686.由（2-乙氧基乙基）丙二烯腈制备吡咯并（3'：2'-3：4）喹诺酮

  摘要：

  DOI：

  10.1039/jr9570003448

文献信息

• Quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
  申请人：SMITHKLINE BEECHAM INTERCREDIT B.V.

  公开号：EP0307078A1

  公开（公告）日：1989-03-15

  in which R¹ to R⁴ are the same or different and are inter alia, each hydrogen, C₁₋₄alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆alkylthio, C₁₋₄alkanoyl, amino, R⁵ to R⁹ are the same or different and are each hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C₁₋₆alkanoyl, trifluoromethyl or nitro, R¹⁰ is inter alia hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, -CH₂OH, C₁₋₆alkylthio, NH(CH₂)nOH in which n is 0 to 4 or amino; and A is -(CH₂)₂-, (CH₂)₃- ­or -CH=CH-; processes for their preparation, pharmaceutical compositions containing them and their use in therapy as inhibitors of gastric acid secretion.

  C₁₋₄烷硫基、C₁₋₄烷酰基、氨基、R⁵至 R⁹相同或不同且各自为氢、C₁₋₆alkyl、C₁₋₆alkoxy、C₁₋₆烷硫基、卤素、氰基、氨基、羟基、氨基甲酰基、羧基、C₁₋₆烷酰基、三氟甲基或硝基，R¹⁰除其他外为氢、C₁₋₆烷基、C₁₋₆烷氧基、卤素、羟基、-CH₂OH、C₁₋₆烷硫基、NH(CH₂)nOH（其中 n 为 0 至 4）或氨基；和 A 是-(CH₂)₂-、(CH₂)₃- 或-CH=CH-；它们的制备工艺、含有它们的药物组合物以及它们作为胃酸分泌抑制剂在治疗中的用途。
• Support for fragrance samples
  申请人：MINNESOTA MINING AND MANUFACTURING COMPANY

  公开号：EP0441034A2

  公开（公告）日：1991-08-14

  Compounds of structure (I): in which R1 to R4 are the same or different and are each hydrogen, C1-4alkyl, C1-6alkoxy, phenyl, C1-6alkylthio, C1-4alkanoyl, amino, C1-6alkylamino, diC1-6alkylamino, halogen, trifluoromethyl or nitro, provided that at least two of R1 to R4 are hydrogen. R5 to R9 are the same or different and are each hydrogen, C1-6alkyl, C1-6alkoxy, C1-6alkylthio, halogen, cyano, amino, hydroxy, carbamoyl, carboxy, C1-6alkanoyl, trifluoromethyl or nitro, provided that at least two of R5 to R9 are hydrogen ; R10 is hydrogen, C1-6alkyl, C1-6alkoxy, halogen, hydroxy, -CH20H, C1-6alkylthio, NH(CH2)nOH in which n is 0 to 4 or a group -NR11R12 in which R11 and R12 are the same or different and are each hydrogen or C1-6alkyl or together with the nitrogen atom to which they are attached form a saturated or unsaturated ring ; and A is -N=N-; or -CH=N-; and pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy as inhibitors of gastric acid secretion and bone resorption.

  结构(I)的化合物： 其中 R1 至 R4 相同或不同，各自为氢、C1-4烷基、C1-6烷氧基、苯基、C1-6烷硫基、C1-4烷酰基、氨基、C1-6烷基氨基、二C1-6烷基氨基、卤素、三氟甲基或硝基，条件是 R1 至 R4 中至少有两个为氢。 R5 至 R9 相同或不同，各自为氢、C1-6烷基、C1-6烷氧基、C1-6烷硫基、卤素、氰基、氨基、羟基、氨基甲酰基、羧基、C1-6烷酰基、三氟甲基或硝基，条件是 R5 至 R9 中至少有两个是氢； R10 是氢、C1-6烷基、C1-6烷氧基、卤素、羟基、- 0H、C1-6烷硫基、NH(CH2)nOH（其中 n 为 0 至 4）或基团-NR11R12（其中 R11 和 R12 相同或不同，且各自为氢或 C1-6 烷基，或与所连接的氮原子一起形成饱和或不饱和环）；以及 A 是-N=N-； 或-CH=N-； 及其药学上可接受的盐、制备工艺、含有它们的药物组合物，以及它们作为胃酸分泌抑制剂和骨吸收抑制剂在治疗中的用途。
• US5051508A
  申请人：——

  公开号：US5051508A

  公开（公告）日：1991-09-24
• US5420135A
  申请人：——

  公开号：US5420135A

  公开（公告）日：1995-05-30